BAP Officer Details

President Elect

Professor Kevin Fone

Kevin Fone

University of Nottingham
President-elect until 2020; President until 2022; Past-President until 2024

Kevin Fone has been Professor of Neuroscience in the School of Life Sciences at the University of Nottingham since 2006. He completed his BSc and PhD in Pharmacology at the University of Liverpool before starting an MRC funded post-doctoral research position in Nottingham, where he has remained since 1984 and helped establish a successful Neuroscience undergraduate degree. His research focus has been to improve our understanding of the neurobiology of common CNS neurodevelopmental disorders, like ADHD and schizophrenia, by developing and validating rodent preclinical models and advancing drug discovery.

Kevin has been an enthusiastic member of the BAP since 1995 and attended every Summer Meeting since. He has served on Council (2003-7), been Meetings Secretary (2004-7), and contributes to the Masterclasses in Clinical Psychopharmacology. He has always supported the BAP aim of bringing together people in academia, health services, and industry regardless of career stage or field of psychopharmacology. He recognises the unique benefits of the BAP as an inclusive forum to foster interactions between clinical and preclinical members, provide support and training for junior members and those in need of academic refreshment, and enhance collaborations between academia, industry and health professionals. If given the privilege to serve in leading roles on BAP Council he would endeavour to ensure these activities continue, both to assist translation of basic psychopharmacology discoveries into clinical advances, and conversely to help preclinical research remain cognisant of clinical practice.

Kevin has been extremely fortunate and grateful to have received collaborative funding from an array of pharmaceutical companies and Research Councils. He has published over 130 peer-reviewed articles, supervised 40 postgraduate students, served on several editorial boards, is a Fellow of the British Pharmacological Society and currently President of the International Society for Serotonin Research.

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. No
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. Heptares Ltd, UK, Roche, Basel, Switzerland
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. No
  21. If there is anything else you feel it necessary to disclose, please provide details below:

Form completed on 8th August 2018